William Blair Analysts Lower Earnings Estimates for VKTX

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Equities researchers at William Blair cut their Q2 2025 earnings per share (EPS) estimates for Viking Therapeutics in a report issued on Wednesday, April 23rd. William Blair analyst A. Hsieh now forecasts that the biotechnology company will post earnings per share of ($0.45) for the quarter, down from their previous forecast of ($0.36). The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share. William Blair also issued estimates for Viking Therapeutics’ Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.87) EPS, Q1 2026 earnings at ($0.54) EPS, Q2 2026 earnings at ($0.55) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at ($2.22) EPS and FY2027 earnings at ($2.79) EPS.

Several other research analysts have also recently issued reports on VKTX. B. Riley reissued a “buy” rating and issued a $96.00 target price (down from $109.00) on shares of Viking Therapeutics in a research report on Friday, February 7th. Maxim Group dropped their target price on Viking Therapeutics from $120.00 to $70.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Raymond James raised their target price on Viking Therapeutics from $122.00 to $125.00 and gave the stock a “strong-buy” rating in a research report on Thursday, February 6th. Scotiabank began coverage on Viking Therapeutics in a research report on Thursday, February 13th. They issued a “sector outperform” rating and a $102.00 target price on the stock. Finally, Piper Sandler dropped their target price on Viking Therapeutics from $74.00 to $71.00 and set an “overweight” rating on the stock in a research report on Thursday, February 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Viking Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $87.15.

Viking Therapeutics Price Performance

Viking Therapeutics stock opened at $25.94 on Monday. The stock has a market capitalization of $2.91 billion, a PE ratio of -25.94 and a beta of 0.84. The business’s fifty day moving average is $26.35 and its 200 day moving average is $40.06. Viking Therapeutics has a one year low of $18.92 and a one year high of $81.86.

Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Wednesday, April 23rd. The biotechnology company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.10). During the same quarter in the prior year, the firm earned ($0.26) earnings per share. The firm’s revenue for the quarter was up .0% compared to the same quarter last year.

Institutional Trading of Viking Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. JNBA Financial Advisors bought a new stake in Viking Therapeutics in the 1st quarter worth approximately $56,000. CNB Bank increased its stake in Viking Therapeutics by 141.6% in the 1st quarter. CNB Bank now owns 5,330 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 3,124 shares during the last quarter. HighMark Wealth Management LLC increased its stake in Viking Therapeutics by 9.4% in the 1st quarter. HighMark Wealth Management LLC now owns 4,660 shares of the biotechnology company’s stock worth $113,000 after acquiring an additional 400 shares during the last quarter. International Assets Investment Management LLC increased its stake in Viking Therapeutics by 50.9% in the 1st quarter. International Assets Investment Management LLC now owns 27,584 shares of the biotechnology company’s stock worth $666,000 after acquiring an additional 9,308 shares during the last quarter. Finally, Oppenheimer & Co. Inc. increased its stake in Viking Therapeutics by 19.4% in the 1st quarter. Oppenheimer & Co. Inc. now owns 144,543 shares of the biotechnology company’s stock worth $3,491,000 after acquiring an additional 23,481 shares during the last quarter. Institutional investors own 76.03% of the company’s stock.

Insider Activity at Viking Therapeutics

In other news, Director Sarah Kathryn Rouan acquired 1,240 shares of Viking Therapeutics stock in a transaction on Monday, March 31st. The shares were acquired at an average price of $24.15 per share, with a total value of $29,946.00. Following the purchase, the director now directly owns 1,240 shares in the company, valued at $29,946. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.10% of the stock is owned by corporate insiders.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.